Early Clinical and Metabolic Response to Tazemetostat in Advanced Relapsed INI1 Negative Epithelioid Sarcoma

References

• JawadMU , ExteinJ , MinES , ScullySP. Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER Database. Clin. Orthop. Relat. Res.467(11), 2939 (2009).
   PubMed Web of Science ®Google Scholar
• ChbaniL , GuillouL , TerrierPet al.Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French Sarcoma Group. Am. J. Clin. Pathol.131(2), 222–227 (2009).
   PubMed Web of Science ®Google Scholar
• MwR. Recurrent epitheloid cell sarcoma of scapular region: a case report and review of literature. JMSCR7(4), 160–165 (2019).
   Google Scholar
• FrezzaAM , BottaL , PasqualiSet al.1486PAn epidemiological insight into epithelioid sarcoma (ES): the open issue of distal-type (DES) versus proximal-type (PES). Ann.Oncol.Vol 28, (2017).
   Web of Science ®Google Scholar
• ArmahHB , ParwaniAV. Epithelioid sarcoma. Arch. Pathol. Lab. Med.133(5), 814–819 (2009).
   PubMed Web of Science ®Google Scholar
• ElsamnaST , AmerK , ElkattawyO , BeebeKS. Epithelioid sarcoma: half a century later. Acta Oncol.59(1), 48–54 (2020).
   PubMed Web of Science ®Google Scholar
• SpillaneAJ , ThomasJM , FisherC. Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann. Surg. Oncol.7(3), 218–225 (2000).
   PubMed Web of Science ®Google Scholar
• HornickJL , DalCin P , FletcherCDM. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am. J. Surg. Pathol.33(4), 542–550 (2009).
   PubMed Web of Science ®Google Scholar
• MobleyBC , McKenneyJK , BangsCDet al.Loss of SMARCB1/INI1 expression in poorly differentiated chordomas. Acta Neuropathol.120(6), 745–753 (2010).
   PubMed Web of Science ®Google Scholar
• KohashiK , OdaY. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci.108(4), 547–552 (2017).
   PubMed Web of Science ®Google Scholar
• FrezzaAM , JonesRL , LoVullo Set al.Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: a multi-institutional case series. JAMA Oncol.4(9), e180219 (2018).
   PubMed Web of Science ®Google Scholar
• RecineF , BongiovanniA , RivaNet al.Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. Onco. Targets Ther.10, 1155–1164 (2017).
   PubMed Web of Science ®Google Scholar
• de VisscherSAHJ , van GinkelRJ , WobbesTet al.Epithelioid sarcoma: still an only surgically curable disease. Cancer107(3), 606–612 (2006).
   PubMed Web of Science ®Google Scholar
• TlemsaniC , DumontS , RopertSet al.Vinorelbine-based chemotherapy in metastatic epithelioid sarcoma. JCO34(Suppl. 15), e22549–e22549 (2016).
   Web of Science ®Google Scholar
• AlimovaI , BirksDK , HarrisPSet al.Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro. Oncol.15(2), 149–160 (2013).
   PubMed Web of Science ®Google Scholar
• KnutsonSK , WarholicNM , WigleTJet al.Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA110(19), 7922–7927 (2013).
   PubMed Web of Science ®Google Scholar
• ItalianoA , SoriaJ-C , ToulmondeMet al.Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumors: a first-in-human, open-label, Phase I study. Lancet Oncol.19(5), 649–659 (2018).
   PubMed Web of Science ®Google Scholar
• GounderM , SchöffskiP , JonesRLet al.Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, Phase II basket study. Lancet Oncol.21(11), 1423–1432 (2020).
   PubMed Web of Science ®Google Scholar
• GuillouL , WaddenC , CoindreJ-M , KrauszT , FletcherCDM. ‘Proximal-type’ epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features: clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am. J. Surg. Pathol.21(2), 130–146 (1997).
   PubMed Web of Science ®Google Scholar
• SpuntSL , FrancotteN , DeSalvo GLet al.Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group (COG) and the European paediatric soft tissue Sarcoma Study Group (EpSSG) prospective clinical trials. Eur. J. Cancer112, 98–106 (2019).
   PubMed Web of Science ®Google Scholar
• GuzzettaAA , MontgomeryEA , LyuHet al.Epithelioid sarcoma: one institution's experience with a rare sarcoma. J. Surg. Res.177(1), 116–122 (2012).
   PubMed Web of Science ®Google Scholar
• SobankoJF , MeijerL , NigraTP. Epithelioid sarcoma. J. Clin. Aesthet. Dermatol.2(5), 49–54 (2009).
   PubMedGoogle Scholar
• RekhiB , GoradBD , ChinoyRF. Clinicopathological features with outcomes of a series of conventional and proximal-type epithelioid sarcomas, diagnosed over a period of 10 years at a tertiary cancer hospital in India. Virchows Arch.453(2), 141–153 (2008).
   PubMed Web of Science ®Google Scholar
• CasanovaM , FerrariA , ColliniPet al.Epithelioid sarcoma in children and adolescents. Cancer106(3), 708–717 (2006).
   PubMed Web of Science ®Google Scholar
• LevyA , LePéchoux C , TerrierPet al.Epithelioid sarcoma: need for a multimodal approach to maximize the chances of curative conservative treatment. Ann. Surg. Oncol.21(1), 269–276 (2014).
   PubMed Web of Science ®Google Scholar
• RutkowskiP , ŁugowskaI. Follow-up in soft tissue sarcomas. Memo7(2), 92–96 (2014).
   PubMedGoogle Scholar
• JonesRL , ConstantinidouA , OlmosDet al.Role of palliative chemotherapy in advanced epithelioid sarcoma. Am. J. Clin. Oncol.35(4), 351–357 (2012).
   PubMed Web of Science ®Google Scholar
• TouatiN , SchöffskiP , LitièreSet al.European organisation for research and treatment of cancer soft tissue and bone sarcoma group experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: clinical profile and response to systemic therapy. Clin. Oncol.30(7), 448–454 (2018).
   PubMed Web of Science ®Google Scholar
• MorschhauserF , TillyH , ChaidosAet al.Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, Phase II trial. Lancet Oncol.21(11), 1433–1442 (2020).
   PubMed Web of Science ®Google Scholar
• SchuetzeSM , BolejackV , ChoyEet al.Phase II study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer123(1), 90–97 (2017).
   PubMed Web of Science ®Google Scholar
• GeoergerB , KangHJ , Yalon-OrenMet al.KEYNOTE-051: an update on the Phase II results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma. JCO36(Suppl. 15), 10525–10525 (2018).
   Web of Science ®Google Scholar
• PaoluzziL , CacavioA , GhesaniMet al.Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin. Sarcoma Res.Vol 6, (2016).
   Google Scholar
• SenS , McKeanMA , SierraLet al.A Phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma. JCO38(Suppl. 15), TPS11573–TPS11573 (2020).
   Web of Science ®Google Scholar